Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting
08 mars 2022 16h30 HE
|
Bio-Path Holdings, Inc.
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
04 mars 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
05 janv. 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
13 déc. 2021 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Third Quarter 2021 Financial Results
12 nov. 2021 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021
05 nov. 2021 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
04 nov. 2021 09h01 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
27 oct. 2021 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
24 août 2021 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
13 août 2021 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...